In re: Lentz et al.

Application No. 10/572,521

Page 2 of 18

## **Listing of Claims**

Please amend the claims as shown below by deleting the material indicated by strike-through or placed within double brackets and adding the underlined material. This listing of claims will replace all prior versions and listings of the claims in this application.

þ

- 1. (Currently amended) A method of evaluating clotting activity in a <u>blood or plasma</u> sample <u>from a subject, the method comprising</u>:
- (a) <u>creating a mixture by combining in vitro the[[a]]</u> blood or plasma sample from the[[a]] subject with:
  - (i) a phospholipid that is soluble in the sample, wherein the phospholipid comprises phospholipids acylated by C4 to C12 fatty acids;
    - (ii) a contact activator; and
    - (iii) calcium;
  - (b) incubating the mixture of (a) above for a time and under conditions sufficient for prothrombin activation; and
  - (c) detecting Factor  $X_a$  or thrombin <u>enzyme</u> activity, wherein the <u>enzyme</u> activity of Factor  $X_a$  or thrombin correlates with clotting factor activity in the sample, thereby evaluating clotting activity in the sample.
- 2. (Original) The method of Claim 1, wherein the sample is from a subject with lupus.
- 3. (Currently amended) The method of Claim 1, wherein the sample is further combined with Activated Protein C or a Protein C activator, wherein the level of thrombin enzyme activity correlates with Activated Protein C resistance in the sample.
- 4. (Currently amended) The method of Claim 3, wherein the sample is further combined with Protein S depleted plasma, wherein the level of thrombin <u>enzyme</u> activity inversely correlates with Protein S levels in the sample.

In re: Lentz et al.

Application No. 10/572,521

Page 3 of 18

5. (Original) The method of Claim 1, wherein the sample is further combined with a plasma selected from the group consisting of (a) plasma known to be deficient for a particular clotting factor and (b) normal plasma.

- 6. (Original) The method of Claim 1, wherein the sample is from a subject that has been given heparin treatment.
- 7. (Original) The method of any of Claims 1-6, wherein thrombin enzymatic activity is measured.
  - 8. (Original) The method of any of Claims 1-6, wherein clot formation is detected.
- 9. (Previously presented) The method of Claim 1, wherein the phospholipid consists essentially of a phospholipid selected from the group consisting of phosphatidylserine, phosphatidylhomoserine, phosphatidic acid, phosphatidylethanolamine, and a combination thereof.
- 10. (Currently amended) The method of Claim 9, wherein the phospholipid consists essentially of phosphatidylserine acylated by C4[2] to C12[4] fatty acids.
- 11. (Previously presented) The method of Claim 1, wherein the phospholipid is added to a final concentration from about 4  $\mu$ M to about 2 mM.
- 12. (Previously presented) The method of Claim 1, wherein the phospholipid is in a dried form prior to combination with the sample.
- 13. (Original) The method of Claim 1, wherein the sample is a human blood or plasma sample.
- 14. (Currently amended) The method of Claim 1, further comprising comparing the detected thrombin <u>enzymatic</u> activity with a standard.

In re: Lentz et al.

Application No. 10/572,521

Page 4 of 18

15. (Original) The method of Claim 1, wherein the contact activator is selected from the group consisting of kaolin, clay, silica, ellagic acid, celite, diatomaceous earth, glass beads, and a combination thereof.

## 16-57. (Canceled)

- 58. (Currently amended) A method of evaluating clotting activity in a <u>blood or plasma</u> sample <u>from a subject</u>, the <u>method</u> comprising:
- (a) <u>creating a mixture by combining in vitro the[[a]]</u> blood or plasma sample from the[[a]] subject with:
  - (i) a phospholipid that is soluble in the sample to a final concentration of 50  $\mu$ M to 2 mM phospholipid, wherein the phospholipid comprises phospholipids acylated by C4 to C12 fatty acids;
    - (ii) a contact activator; and
    - (iii) calcium;
  - (b) incubating the mixture of (a) above for a time and under conditions sufficient for prothrombin activation; and
  - (c) detecting Factor  $X_a$  or thrombin <u>enzyme</u> activity, wherein the <u>enzyme</u> activity of Factor  $X_a$  or thrombin correlates with clotting factor activity in the sample, thereby evaluating clotting activity in the sample.
- 59. (Currently amended) The method of Claim 58, wherein the phospholipid is added to a final concentration of [[2]] $\underline{1}00 \,\mu\text{M}$  to 2 mM.
- 60. (Currently amended) The method of Claim 58, wherein the phospholipid emprises consists essentially of phospholipids acylated by C4 to C12 fatty acids.
- 61. (Previously presented) The method of Claim 58, wherein the sample is from a subject with lupus.
- 62. (Currently amended) A method of evaluating clotting activity in a <u>blood or plasma</u> sample <u>from a subject</u>, the <u>method comprising</u>:

In re: Lentz et al.

Application No. 10/572,521

Page 5 of 18

- (a) <u>creating a mixture by combining in vitro the[[a]]</u> blood or plasma sample from the[[a]] subject with:
  - (i) a phospholipid that is soluble in the sample and contains no detectable aggregates as determined by quasi-electric light scattering techniques, wherein the phospholipid comprises phospholipids acylated by C4 to C12 fatty acids;
    - (ii) a contact activator; and
    - (iii) calcium;
  - (b) incubating the mixture of (a) above for a time and under conditions sufficient for prothrombin activation; and
  - (c) detecting Factor  $X_a$  or thrombin <u>enzyme</u> activity, wherein the <u>enzyme</u> activity of Factor  $X_a$  or thrombin correlates with clotting factor activity in the sample, thereby evaluating clotting activity in the sample.
- 63. (Previously presented) The method of Claim 62, wherein the phospholipid is added to a final concentration of 50  $\mu$ M to 2 mM.
- 64. (Currently amended) The method of Claim 62, wherein the phospholipid is added to a final concentration of [[2]] $\underline{1}$ 00  $\mu$ M to 2 mM.
- 65. (Currently amended) The method of Claim 62, wherein the phospholipid emprises consists essentially of phospholipids acylated by C4 to C12 fatty acids.
- 66. (Previously presented) The method of Claim 62, wherein the sample is from a subject with lupus.
- 67. (Currently amended) A method of evaluating clotting activity in a <u>blood or plasma</u> sample <u>from a subject, the method comprising</u>:
- (a) <u>creating a mixture by combining in vitro the[[a]]</u> blood or plasma sample from the[[a]] subject with:
  - (i) a phospholipid that is soluble in the sample and consists essentially of phospholipids acylated by <u>C4</u>[[C2]] to <u>C12</u>[[C14]] fatty acids;
    - (ii) a contact activator; and

In re: Lentz et al.

Application No. 10/572,521

Page 6 of 18

- (iii) calcium;
- (b) incubating the mixture of (a) above for a time and under conditions sufficient for prothrombin activation; and
- (c) detecting Factor  $X_a$  or thrombin <u>enzyme</u> activity, wherein the <u>enzyme</u> activity of Factor  $X_a$  or thrombin correlates with clotting factor activity in the sample, thereby evaluating clotting activity in the sample.
- 68. (Previously presented) The method of Claim 67, wherein the phospholipid is added to a final concentration of 50  $\mu M$  to 2 mM.

. 1

- 69. (Currently amended) The method of Claim 67, wherein the phospholipid is added to a final concentration of [[2]] $\underline{1}$ 00  $\mu$ M to 2 mM.
- 70. (Previously presented) The method of Claim 67, wherein the phospholipid consists essentially of phospholipids acylated by C4 to C10 fatty acids.
- 71. (Previously presented) The method of Claim 67, wherein the sample is from a subject with lupus.
- 72. (New) The method of Claim 1, wherein the phospholipid consists essentially of phospholipids acylated by C4 to C12 fatty acids.